Table 6 Treatment response of patients with chronic ITP with IL-4 and IL-4Rα

All treatment, no. of cases (%)

14

(82.4)

83

(76.1)

0.76

1.39

0.37–5.22

71

(80.7)

26

(68.4)

0.10

2.08

0.87–4.97

Second line treatment, no. of cases (%)

9

(52.9)

28

(25.7)

0.04

3.25

1.15–9.25

29

(33.0)

8

(21.1)

0.21

1.84

0.75–4.52

 CR, no. of cases (%)

9

(64.3)

59

(71.1)

0.75

0.73

0.22–2.41

50

(70.4)

18

(69.2)

1.00

1.06

0.40–2.81

 RR (CR+R), no. of cases (%)

13

(92.9)

79

(95.2)

0.55

0.66

0.68–6.36

68

(95.8)

24

(92.3)

0.61

1.89

0.30–12.00

Prednisolone therapy, no. of cases (%)

12

(70.6)

70

(64.2)

0.79

1.34

0.44–4.08

62

(70.5)

20

(52.6)

0.05

2.15

0.98–4.70

 CR, no. of cases (%)

5

(41.7)

40

(57.1)

0.36

0.54

0.16–1.85

34

(54.8)

11

(55.0)

1.00

0.99

0.36–2.74

 RR (CR+R), no. of cases (%)

10

(83.3)

64

(91.4)

0.33

0.47

0.08–2.65

56

(90.3)

18

(90.0)

1.00

1.04

0.19–5.60

Splenectomy, no. of cases (%)

5

(29.4)

14

(12.8)

0.14

2.83

0.87–9.24

15

(17.0)

4

(10.5)

0.43

1.75

0.54–5.66

 CR, no. of cases (%)

4

(80.0)

7

(50.0)

0.34

4.00

0.35–45.38

7

(46.7)

4

(100)

0.10

 RR (CR+R), no. of cases (%)

5

(100)

9

(64.3)

0.26

10

(66.7)

4

(100)

0.53

Eradication of Helicobacter pylori, no. of cases (%)

7

(41.2)

36

(33.6)

0.59

1.38

0.49–3.93

33

(37.9)

10

(27.0)

0.24

1.65

0.71–3.84

 CR, no. of cases (%)

4

(57.1)

16

(44.4)

0.69

1.67

0.33–8.55

15

(45.5)

5

(50.0)

1.00

0.83

0.20–3.44

Severe ITP, no. of cases (%)

5

(29.4)

19

(17.4)

0.32

1.97

0.62–6.26

19

(21.6)

5

(13.2)

0.33

1.82

0.62–5.29

Refractory ITP, no. of cases (%)

0

(0)

10

(9.2)

0.36

9

(10.2)

1

(2.6)

0.28

4.22

0.52–34.51

Corticosteroid-dependent, no. of cases (%)

5

(33.3)

32

(30.2)

0.77

1.16

0.37–3.66

28

(33.3)

9

(24.3)

0.39

1.56

0.65–3.74